Navigation Links
BARC Announces Long-Term Cooperation In South African Biobanking for HIV Vaccine Trials

JOHANNESBURG, South Africa, May 21 /PRNewswire/ -- BARC, a global central laboratory today announced a broad biobanking agreement to support HIV vaccine trials currently being performed in South Africa by the HIV Vaccine Trials Network (HVTN).

The HVTN vaccine trials are designed to answer scientific questions that will advance knowledge and ultimately lead to a safe and effective vaccine to prevent HIV infection. The HVTN is supported through a cooperative agreement with the National Institute of Allergy and Infectious Diseases, a component of the U.S. National Institutes of Health. HVTN trials in South Africa are conducted in conjunction with the South African AIDS Vaccine Initiative.

Since October last year, BARC has performed peripheral blood mononuclear cell (PBMC)-isolation services for the HVTN HIV vaccine trials at various locations in South Africa. Under the new agreement, these services are extended to include the biobanking management services for all HVTN-related vaccine projects in South Africa. It is expected that during the next five years, hundreds of thousands of samples will be handled and managed at BARC's facilities in Johannesburg.

For this operation, BARC South Africa will be increasing its capacity and space of its premises in Johannesburg. In addition to its offices there, BARC also has important lab facilities in Durban, Cape Town, and Pretoria.

Julie McElrath, Director of the HVTN laboratory program said, "This agreement with BARC ensures that these clinical trials can be carried out in a cost-effective manner according to the highest quality standards expected by the international AIDS research community."

According to Dr. Peter Cole, the CEO of BARC South Africa, "This agreement provides BARC with the opportunity to make a major contribution towards the development of an HIV vaccine to help prevent the spread of AIDS in Africa. At the same time, this agreement expands BARC's role in South Africa as the key provider of global central lab services for clinical trials."

Rudi Marien, CEO of BARC group said, "This alliance emphasizes the growing strength of BARC in continents other than in the U.S. and Europe. It also confirms that BARC has grown into a highly recognized provider of biobanking services, given its ability to manage millions of patient samples for major international clinical trials."

For more information, please contact


BARC South Africa,

Dr. Jessica Trusler, Medical Director

Tel +27 11 358 07 47


Mr. Scott Keddy, Sr. Director Business Development

Tel: +1 516 719 1052

BARC Europe,

Dr. Guy Dewil, COO

Tel + 329 329 2 327

BARC is an independent global central laboratory, with subsidiaries in USA, Europe, South Africa, Australia, China, as well as a network of laboratories Asia and South America. BARC supports the pharmaceutical and biotechnology industry in the development and approval of new therapeutic agents by managing the laboratory component of clinical trials. BARC is committed to providing central laboratory services, including biobanking, that meet the highest quality standards, with rapid delivery of laboratory data. Worldwide testing is performed on equivalent instrumentation and integrated into a single global database with identical reference ranges and report.

BARC South Africa Pty., Ltd., established in 1999, is the South African arm of BARC, The local head office is in Johannesburg, with branch offices in Durban, Pretoria and Cape Town. BARC S.A. is a joint venture between BARC and LANCET LABORATORIES the foremost independent clinical pathology laboratory in South Africa. LANCET LABORATORIES brings a wealth of local knowledge to the joint venture, having provided a pathology service to the medical community since 1952. The joint venture allows for provision of LANCET LABORATORIES expertise to BARC S.A.

The HVTN is an international collaboration of scientists and institutions whose goal is to accelerate the search for an HIV vaccine by sharing trial results and facilitating parallel, concurrent testing. The HVTN is a unique hybrid that combines the depth and diversity of the academic community and the flexibility of a commercial drug company. Working with industry and government, the HVTN seeks to expedite and coordinate the trial process, advancing vaccine candidates and building a body of knowledge around HIV vaccine trials. The HVTN is funded through a cooperative agreement with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health, an agency of the U.S. Department of Health and Human Services (DHHS). The HVTN comprises more than 25 research institutions worldwide, coordinated from its headquarters at the Fred Hutchinson Cancer Research Center in Seattle, Washington.

SOURCE BARC Central Laboratory
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder
2. QuatRx Pharmaceuticals Announces Presentation of Further Data from Ophena(TM) (Ospemifene) Phase 3 Study for Treatment of Symptoms of Vulvovaginal Atrophy
3. Alba Therapeutics Announces the Presentation of Results of a Phase IIa Clinical Trial for Larazotide Acetate for the Treatment of Celiac Disease at the Digestive Disease Week Conference
4. PTC Therapeutics Announces Data Supporting Cough Frequency as a New Outcome Measure in Evaluating Treatments for Cystic Fibrosis
5. Telik Announces Initiation of Two Phase 2 Randomized TELINTRA Studies
6. Omeros Announces Initiation of Patient Enrollment in OMS201 Phase 1 Study
7. Fuisz Tobacco Announces Clinical Study Results for Fuisz Tobacco Sheet Strip; Super Enhanced Bioavailability of Nicotine From Its Tobacco Sheet Strip Supports Efficacy of Low Dose Tobacco Product
8. InterMune Announces Receipt of Fast Track Designation for Pirfenidone From FDA
9. Ipsogen Announces Three Studies at the American Society of Clinical Oncology (ASCO) Meeting Extending the Utility of the Genomic Grade Index for Predicting Response to Chemotherapy in Breast Cancer
10. TAP Pharmaceutical Products Inc. Announces Phase 3 TAK-390MR Data Demonstrating Higher Overall Healing Versus Lansoprazole in Patients with Erosive Esophagitis
11. Pulmo BioTech Announces Details of the Methodology for its Phase I Human Trials
Post Your Comments:
(Date:12/1/2015)... , Dec. 2, 2015  A combination of detailed ... the first time in the surgical planning for separation of ... annual meeting of the Radiological Society of North ... --> Conjoined twins, or twins whose bodies are connected, ... rates are low and separating them through surgery is extremely ...
(Date:12/1/2015)... , Dec. 1, 2015  A large study ... drug tamoxifen while taking an antidepressant found no increased ... today in The Journal of the National Cancer Institute. ... Tamoxifen is a commonly prescribed generic drug taken by ... developing a recurrence. Tamoxifen is recommended for five years, ...
(Date:12/1/2015)... Wash. and VANCOUVER , ... Committee (DMC) meeting, OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI ... is continuing based on the pre-planned interim futility analysis ... review, no new safety issues were identified by the ... all analyses and final results are expected in the ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... December 02, 2015 , ... The National Association ... 2015-2016 inductee into its VIP Woman of the Year Circle. She is recognized ... networking organization exclusively for professional women, boasting 850,000 members and over 200 operating ...
(Date:12/1/2015)... ... December 02, 2015 , ... Ruth Pearson was struggling. ... flare-up. Unable to walk without assistance and quickly losing hope of recovering her former ... miracle happened. , Pearson was attending a women’s retreat when she experienced a particularly ...
(Date:12/1/2015)... ... December 02, 2015 , ... ... as a 2015-2016 inductee into its VIP Woman of the Year Circle. ... the nation’s leading networking organization exclusively for professional women, boasting 850,000 members and, ...
(Date:12/1/2015)... NY (PRWEB) , ... December 02, 2015 , ... ... honors Jessica Clark as a 2015-2016 inductee into its VIP Woman of the ... NAPW is the nation’s leading networking organization exclusively for professional women, boasting 850,000 ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... Trustify is ... in Washington, DC, hosted by Becky’s Fund, an organization dedicated to ending domestic violence. ... and control back to battered victims and survivors of domestic violence. Trustify is also ...
Breaking Medicine News(10 mins):